 Carolyn Lefkowits
Concepts (166)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genital Neoplasms, Female | 20 | 2023 | 99 | 6.490 |
Why?
| | Cancer Pain | 6 | 2019 | 36 | 2.710 |
Why?
| | Palliative Care | 15 | 2023 | 1002 | 2.320 |
Why?
| | Analgesics, Opioid | 7 | 2021 | 1143 | 1.760 |
Why?
| | Pain Management | 5 | 2021 | 405 | 1.470 |
Why?
| | Endometrial Neoplasms | 5 | 2025 | 208 | 1.340 |
Why?
| | Medical Oncology | 8 | 2022 | 332 | 1.310 |
Why?
| | Surgical Oncology | 3 | 2019 | 30 | 1.290 |
Why?
| | Gynecology | 7 | 2020 | 178 | 1.250 |
Why?
| | Hot Flashes | 3 | 2013 | 88 | 1.070 |
Why?
| | Hospice Care | 2 | 2023 | 218 | 0.760 |
Why?
| | Terminal Care | 3 | 2023 | 279 | 0.720 |
Why?
| | Referral and Consultation | 4 | 2017 | 851 | 0.690 |
Why?
| | Opioid-Related Disorders | 5 | 2019 | 600 | 0.620 |
Why?
| | Communication | 3 | 2020 | 965 | 0.550 |
Why?
| | Practice Guidelines as Topic | 2 | 2016 | 1560 | 0.520 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2019 | 267 | 0.470 |
Why?
| | Attitude of Health Personnel | 3 | 2019 | 1185 | 0.470 |
Why?
| | Perinatal Care | 1 | 2016 | 62 | 0.470 |
Why?
| | Neoplasm Recurrence, Local | 4 | 2025 | 1137 | 0.450 |
Why?
| | Neoplasms | 2 | 2021 | 2875 | 0.430 |
Why?
| | Palliative Medicine | 1 | 2014 | 24 | 0.420 |
Why?
| | Obstetrics and Gynecology Department, Hospital | 1 | 2014 | 6 | 0.420 |
Why?
| | Oncology Service, Hospital | 1 | 2014 | 15 | 0.420 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2026 | 132 | 0.410 |
Why?
| | Female | 34 | 2026 | 78271 | 0.400 |
Why?
| | Cyclohexanecarboxylic Acids | 1 | 2013 | 17 | 0.380 |
Why?
| | Ambulatory Care | 2 | 2017 | 600 | 0.380 |
Why?
| | Ovarian Neoplasms | 3 | 2026 | 586 | 0.380 |
Why?
| | Amines | 1 | 2013 | 39 | 0.380 |
Why?
| | Cost of Illness | 1 | 2014 | 321 | 0.360 |
Why?
| | Oncologists | 3 | 2022 | 46 | 0.350 |
Why?
| | Complementary Therapies | 1 | 2013 | 94 | 0.350 |
Why?
| | Needs Assessment | 1 | 2014 | 404 | 0.350 |
Why?
| | Quality of Life | 8 | 2026 | 3185 | 0.340 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2013 | 192 | 0.340 |
Why?
| | Humans | 37 | 2026 | 144759 | 0.330 |
Why?
| | Analgesics | 1 | 2013 | 228 | 0.330 |
Why?
| | Radiosurgery | 2 | 2025 | 400 | 0.310 |
Why?
| | Guideline Adherence | 1 | 2014 | 589 | 0.300 |
Why?
| | Hospice and Palliative Care Nursing | 2 | 2022 | 113 | 0.300 |
Why?
| | Education, Medical, Graduate | 1 | 2014 | 557 | 0.290 |
Why?
| | Employment | 2 | 2021 | 188 | 0.290 |
Why?
| | Middle Aged | 18 | 2025 | 35875 | 0.290 |
Why?
| | Prostatic Neoplasms | 2 | 2013 | 974 | 0.280 |
Why?
| | Health Services Accessibility | 1 | 2016 | 1098 | 0.270 |
Why?
| | Aged | 14 | 2025 | 25913 | 0.270 |
Why?
| | Epidemics | 2 | 2018 | 98 | 0.250 |
Why?
| | Neoplasm Grading | 2 | 2025 | 307 | 0.250 |
Why?
| | Aged, 80 and over | 6 | 2025 | 8265 | 0.230 |
Why?
| | Acceptance and Commitment Therapy | 1 | 2026 | 30 | 0.230 |
Why?
| | Neoplasm Staging | 3 | 2025 | 1462 | 0.220 |
Why?
| | Advance Care Planning | 2 | 2020 | 243 | 0.210 |
Why?
| | Adult | 13 | 2025 | 40449 | 0.210 |
Why?
| | Fatigue | 1 | 2026 | 366 | 0.200 |
Why?
| | Medical Futility | 1 | 2023 | 31 | 0.200 |
Why?
| | Breast Neoplasms | 2 | 2013 | 2452 | 0.190 |
Why?
| | Gynecologic Surgical Procedures | 2 | 2020 | 64 | 0.190 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2025 | 1953 | 0.190 |
Why?
| | Combined Modality Therapy | 1 | 2025 | 1266 | 0.180 |
Why?
| | Patient Care Team | 2 | 2019 | 689 | 0.180 |
Why?
| | Antineoplastic Agents, Hormonal | 2 | 2013 | 194 | 0.170 |
Why?
| | Indoles | 1 | 2025 | 501 | 0.170 |
Why?
| | Disease Management | 1 | 2025 | 645 | 0.170 |
Why?
| | Brachytherapy | 2 | 2019 | 134 | 0.160 |
Why?
| | Retrospective Studies | 7 | 2022 | 17066 | 0.160 |
Why?
| | Cohort Studies | 4 | 2021 | 5960 | 0.160 |
Why?
| | Ethics, Medical | 1 | 2020 | 87 | 0.150 |
Why?
| | Enoxaparin | 1 | 2020 | 67 | 0.150 |
Why?
| | Hospices | 1 | 2020 | 89 | 0.140 |
Why?
| | Carcinoma, Endometrioid | 1 | 2019 | 51 | 0.140 |
Why?
| | Infection Control | 1 | 2020 | 172 | 0.140 |
Why?
| | Carcinosarcoma | 1 | 2018 | 23 | 0.140 |
Why?
| | Pyridones | 1 | 2020 | 199 | 0.140 |
Why?
| | Postoperative Care | 1 | 2020 | 288 | 0.130 |
Why?
| | Uterine Neoplasms | 1 | 2018 | 96 | 0.130 |
Why?
| | Disease-Free Survival | 1 | 2019 | 769 | 0.130 |
Why?
| | Young Adult | 5 | 2020 | 14105 | 0.130 |
Why?
| | Drug Prescriptions | 1 | 2019 | 284 | 0.130 |
Why?
| | beta Catenin | 1 | 2019 | 252 | 0.120 |
Why?
| | Drug and Narcotic Control | 1 | 2016 | 24 | 0.120 |
Why?
| | Perinatal Death | 1 | 2016 | 26 | 0.120 |
Why?
| | Preoperative Care | 1 | 2019 | 379 | 0.120 |
Why?
| | Cancer Care Facilities | 1 | 2017 | 48 | 0.120 |
Why?
| | Survival Analysis | 1 | 2020 | 1382 | 0.120 |
Why?
| | Truth Disclosure | 1 | 2016 | 50 | 0.120 |
Why?
| | Nausea | 1 | 2016 | 111 | 0.120 |
Why?
| | Life Expectancy | 1 | 2016 | 72 | 0.120 |
Why?
| | Pyrazoles | 1 | 2020 | 509 | 0.120 |
Why?
| | Databases, Factual | 2 | 2019 | 1486 | 0.120 |
Why?
| | Venous Thromboembolism | 1 | 2020 | 324 | 0.120 |
Why?
| | Mood Disorders | 1 | 2016 | 140 | 0.110 |
Why?
| | Self Efficacy | 1 | 2019 | 414 | 0.110 |
Why?
| | Cancer Survivors | 1 | 2020 | 327 | 0.110 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 384 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 378 | 0.110 |
Why?
| | Anticoagulants | 1 | 2020 | 722 | 0.110 |
Why?
| | Program Evaluation | 1 | 2019 | 948 | 0.110 |
Why?
| | Outpatients | 2 | 2017 | 442 | 0.100 |
Why?
| | Physician-Patient Relations | 1 | 2019 | 585 | 0.100 |
Why?
| | Evidence-Based Medicine | 1 | 2018 | 732 | 0.100 |
Why?
| | Hospitalization | 2 | 2014 | 2433 | 0.100 |
Why?
| | Patient Education as Topic | 1 | 2019 | 780 | 0.100 |
Why?
| | Stellate Ganglion | 1 | 2013 | 6 | 0.100 |
Why?
| | Brain Neoplasms | 1 | 2022 | 1318 | 0.100 |
Why?
| | Clonidine | 1 | 2013 | 33 | 0.100 |
Why?
| | Symptom Assessment | 1 | 2014 | 137 | 0.090 |
Why?
| | Societies, Medical | 1 | 2016 | 887 | 0.090 |
Why?
| | Ovariectomy | 1 | 2013 | 162 | 0.090 |
Why?
| | Tamoxifen | 1 | 2013 | 217 | 0.090 |
Why?
| | Hormone Replacement Therapy | 1 | 2013 | 106 | 0.090 |
Why?
| | Anxiety | 1 | 2019 | 1109 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1694 | 0.090 |
Why?
| | Drug Interactions | 1 | 2013 | 398 | 0.090 |
Why?
| | Nerve Block | 1 | 2013 | 103 | 0.090 |
Why?
| | Continuity of Patient Care | 1 | 2014 | 291 | 0.080 |
Why?
| | Mass Screening | 1 | 2020 | 1347 | 0.080 |
Why?
| | Pain | 1 | 2016 | 779 | 0.080 |
Why?
| | Data Collection | 1 | 2014 | 633 | 0.080 |
Why?
| | Fellowships and Scholarships | 1 | 2014 | 357 | 0.080 |
Why?
| | Treatment Outcome | 1 | 2025 | 11679 | 0.080 |
Why?
| | Multivariate Analysis | 1 | 2014 | 1539 | 0.080 |
Why?
| | Depression | 1 | 2019 | 1558 | 0.070 |
Why?
| | Follow-Up Studies | 2 | 2018 | 5408 | 0.070 |
Why?
| | Colorado | 1 | 2019 | 4564 | 0.070 |
Why?
| | Logistic Models | 1 | 2014 | 2117 | 0.070 |
Why?
| | Adolescent | 4 | 2020 | 22428 | 0.070 |
Why?
| | Chemoradiotherapy | 2 | 2020 | 237 | 0.070 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2019 | 222 | 0.070 |
Why?
| | Quality Improvement | 1 | 2016 | 1289 | 0.070 |
Why?
| | Postoperative Complications | 1 | 2020 | 2919 | 0.070 |
Why?
| | Curriculum | 1 | 2014 | 1059 | 0.060 |
Why?
| | Severity of Illness Index | 1 | 2014 | 2925 | 0.060 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2026 | 1720 | 0.060 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 6048 | 0.060 |
Why?
| | United States | 3 | 2020 | 15966 | 0.060 |
Why?
| | Maintenance Chemotherapy | 1 | 2025 | 42 | 0.060 |
Why?
| | Infant, Newborn | 1 | 2016 | 6429 | 0.050 |
Why?
| | Risk Factors | 2 | 2019 | 10779 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2021 | 3604 | 0.050 |
Why?
| | Cranial Irradiation | 1 | 2022 | 85 | 0.050 |
Why?
| | Health Benefit Plans, Employee | 1 | 2020 | 26 | 0.040 |
Why?
| | Unemployment | 1 | 2020 | 42 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2025 | 2029 | 0.040 |
Why?
| | Resource Allocation | 1 | 2020 | 53 | 0.040 |
Why?
| | Standard of Care | 1 | 2020 | 80 | 0.040 |
Why?
| | Prospective Studies | 2 | 2026 | 7990 | 0.040 |
Why?
| | DNA Polymerase II | 1 | 2019 | 35 | 0.040 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 36 | 0.040 |
Why?
| | Microsatellite Instability | 1 | 2019 | 54 | 0.040 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 108 | 0.040 |
Why?
| | PTEN Phosphohydrolase | 1 | 2019 | 164 | 0.030 |
Why?
| | SEER Program | 1 | 2018 | 224 | 0.030 |
Why?
| | Betacoronavirus | 1 | 2020 | 286 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2018 | 421 | 0.030 |
Why?
| | Telemedicine | 1 | 2026 | 945 | 0.030 |
Why?
| | Male | 2 | 2013 | 72315 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2019 | 529 | 0.030 |
Why?
| | Critical Care | 1 | 2020 | 695 | 0.030 |
Why?
| | Prognosis | 1 | 2022 | 4282 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2019 | 1166 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2019 | 1313 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 2115 | 0.020 |
Why?
| | Mutation | 1 | 2019 | 4089 | 0.020 |
Why?
| | Risk Assessment | 1 | 2017 | 3671 | 0.020 |
Why?
| | Pregnancy | 1 | 2020 | 7190 | 0.020 |
Why?
|
|
Lefkowits's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|